<!DOCTYPE html>
<html lang="en">
    <head>
        <title>displaCy</title>
    </head>

    <body style="font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr">
<figure style="margin-bottom: 6rem">
<div class="entities" style="line-height: 2.5; direction: ltr">Available online at www.sciencedirect.com</br></br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ScienceDirect
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br></br>Chronic Diseases and Translational Medicine 5 (2019) 6e14</br></br>Perspective</br></br>www.keaipublishing.com/en/journals/cdtm/</br>www.cdatm.org</br></br>Managing cardiotoxicity associated with immune checkpoint</br></br>inhibitors</br></br>Sireesha Upadhrasta a, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Hadi Elias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 a, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Keval Patel
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 b, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lei Zheng
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 c,*</br></br>a 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Department of Internal Medicine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Saint Agnes Hospital
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Baltimore
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    MD 21229
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    USA

    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
b 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Department of Internal Medicine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    University of Maryland
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Baltimore
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
, 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    MD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
 21201, 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    USA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
</br></br>c Departments of Oncology and 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Surgery
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    The Pancreatic Cancer Precision Medicine Center of Excellence Program
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    The Bloomberg-Kimmel

Institute
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 for Cancer Immunotherapy, 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Baltimore
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
, 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    MD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
 21287, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    USA


    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
Received 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    9 December 2018
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
</br></br>Available online 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    21 March 2019
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
</br></br>Abstract</br></br>Immuno-oncology is a fast evolving ﬁeld of cancer therapy and immune checkpoint inhibitors (ICIs) are clearly a breakthrough</br>in this ﬁeld. Cardiotoxicity with conventional anti-cancer therapies has been well studied in the past and clear guidelines for</br>management of these side effects are available in the literature. However, cardiotoxicity with novel agents such as ICIs has been</br>fairly under-reported and/or underestimated and we are yet to formulate clear guidelines for management of these rare side effects.</br>In 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    the last few years
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
, there has been an overall increase in the number of cases of cardiotoxicity related to ICIs. In this literature</br>review, we describe the mechanism of action of the most widely used ICIs and their related cardiotoxicities. The increase in number</br>of case reports about the potential of cardiotoxicities with these novel agents clearly indicates the need for a new insight into the</br>ﬁeld of cardio-immuno-oncology.</br>© 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2019
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Chinese Medical Association
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. Production and hosting by 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Elsevier B.V.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 on behalf of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    KeAi Communications Co.,
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 Ltd. This is</br>an open access article under the 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CC BY
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</br></br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Keywords
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
: 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Immune
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 checkpoint inhibitor; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Cardiotoxicity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Ipilimumab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Nivolumab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Pembrolizumab

Introduction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br></br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Immune
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 system inhibitory pathways such as cyto-</br>toxic T lymphocyte associated antigen 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (CTLA-4),</br></br>* Corresponding author. 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1650
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
 Orleans Street, CRB1, Room 351,</br>
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Baltimore
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
, 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    MD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    21287
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
, 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    USA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
. Fax: þ1 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    410 614
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 8217.</br>E-mail address: lzheng6@jhmi.edu (
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    L. Zheng
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
).</br>Peer review under responsibility of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Chinese Medical Association
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
.</br></br>Production and Hosting by Elsevier on behalf of 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    KeAi
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
</br></br>programmed cell death ligand 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (PD-L1), and pro-</br>grammed cell death 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (PD-1) are natural checkpoints</br>that dampen the anti-tumor responses of T cells and</br>also play an important role in the prevention of auto-</br>immune diseases.1,2 These pathways can be misused</br>by tumor cells to escape immunologic antitumor re-</br>sponses. Studies by 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Allison
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 et al3 helped better un-</br>derstand the exploitation of these pathways by tumor</br>cells. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    One
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 way that cancer cells can escape adaptive</br>immunity is by clonal selection of non-immunogenic</br>tumor cells during the immune editing process. Im-</br>mune editing is a dynamic process that consists of</br>It</br>immunosurveillance</br></br>progression.</br></br>tumor</br></br>and</br></br>https://doi.org/10.1016/j.cdtm.2019.02.004</br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2095-882X/
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
© 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2019
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Chinese Medical Association
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. Production and hosting by 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Elsevier B.V.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 on behalf of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    KeAi Communications Co.,
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 Ltd. This is an</br>open access article under the 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CC BY
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</br></br>S. Upadhrasta et al. / Chronic Diseases and Translational Medicine 5 (2019) 6e14</br></br>7</br></br>highlights the dual role of immune system and further</br>enhances the importance of immune checkpoints in</br>preventing tumor progression.</br></br>Immune checkpoint inhibitors (ICIs) are anticancer</br>drugs that work by disinhibiting T-cell activity by</br>interfering with checkpoint molecules and thus result</br>in T-cell activation and enhanced antitumor immune</br>response.4,5 The development of ICIs has marked a</br>new era in the ﬁeld of oncology. Monoclonal anti-</br>bodies targeting the aforementioned checkpoint mole-</br>cules have shown promising results in terms of</br>prognosis</br>hematological</br>malignancies.6e8</br></br>tumors</br></br>solid</br></br>and</br></br>for</br></br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Ipilimumab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, ﬁrst</br></br>introduced in 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2010
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
,</br></br>targeting</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CTLA-4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 revolutionized the treatment of melanoma.</br>Since then many other monoclonal antibodies have</br>been introduced,</br>targeting both PD-1 (nivolumab,</br>pembrolizumab) and PD-L1 (atezolizumab, durvalu-</br>mab, avelumab). These drugs have shown deﬁnite</br>improvement in survival in different cancers (Table</br>1).9e12 However, increasingly, case reports have un-</br>veiled a wide range of side effects from activation of</br>immune system with these agents.9,13e15 These side</br>effects are more commonly referred to as immune-</br>related adverse events (IRAEs). IRAEs are generally</br>low grade and easily manageable when detected in a</br>timely manner.</br></br>IRAEs could include a wide spectrum of organ</br>systems such as skin, endocrine, gastrointestinal, pul-</br>monary system and other</br>rare toxicities include</br>neurological, cardiac and renal system. The most</br>commonly reported toxicities are rash, pruritus and</br>vitiligo, hypothyroidism more than hyperthyroidism,</br>diarrhea and episodes of hepatitis and pneumonitis.</br>Both 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    American Society of Clinical Oncology
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 (
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ASCO
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
)</br>and 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    European Society of Medical Oncology
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 (
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ESMO
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
)</br>have published recommendations for the management</br>of some of the common IRAEs.16,17</br></br>Pathophysiology</br></br>Tumor cells use multiple mechanisms to avoid</br>immune destruction: the ﬁrst is by inhibition of T-cell</br>activation through 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CTLA-4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 and the 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    second
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORDINAL</span>
</mark>
 through the</br>promotion of effector T-cell programmed cell death</br>and inhibition of</br>tumor cell apoptosis which is</br>mediated by 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    PD-1/PD-L1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 interaction.18,19 ICIs target</br>PD-1, PD-L1 and 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CTLA-4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 thus inhibiting the tumor</br>cells from inactivating the immune system which</br>leads to restoration of its role against the tumor cells.5</br>This immune stimulation is associated with IRAEs</br>which could occur at any time and it depends on the</br></br>of</br></br>type</br>ICIs,</br>characteristics.</br></br>type of</br></br>cancer</br></br>and the host</br></br>The exact mechanism of cardiac IRAEs remains</br>poorly understood; however, it is likely related to the</br>direct</br>inhibition of PD-1 and 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CTLA-4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
. Studies</br>involving PD-1 deﬁcient mice and CTLA-4 knockout</br>mice, shed light into the fact that genetic manipulation</br>of the PD-1 and 
<mark class="entity" style="background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CTLA-4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PRODUCT</span>
</mark>
 axis could be playing a role</br>in the development of fatal myocarditis, although there</br>is a notable difference in the mechanism of action of</br>these agents.20e23</br></br>PD-1 is a co-inhibitory member of the B7/cluster of</br>differentiation 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    28
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (CD28) superfamily of molecules. It</br>is expressed on the surface of activated T cells and</br>interacts with its ligands PD-L1 and programmed cell</br>death ligand 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (PD-L2) to deliver inhibitory signals</br>to T cell activation. Expression of PD-1 is induced by</br>physiologic activation on T cells, B cells and macro-</br>phages. Studies done by Tarrio et al24 demonstrated</br>that there was an increased inﬂammation, enhanced</br>serum markers of immune damage and increased</br>inﬁltration of CD8</br>T cells as</br>þ</br>compared to PD-1</br>T cell</br>mediated adoptive transfer model. Other studies by</br>Nishimura et al25,26 demonstrated that disruption of the</br>gene encoding PD-1 in mice caused dilated cardio-</br>myopathy. Genetic deletion of PD-L1/PD-L2 and</br>treatment with anti-PD-L1 antibodies were shown to</br>transform transient myocarditis into a lethal form of</br>the disease. Studies in mouse models also showed a</br>protective effect of PD-1 against inﬂammation and</br>myocyte damage.20e22</br></br>T cells in PD-1</br>/CD8</br></br>T cells in a CD8</br></br>/CD8</br></br>þ</br>þ</br></br> </br></br>þ</br></br>þ</br></br>CTLA-4 is an inhibitory co-receptor, expressed</br>almost exclusively on T cells, and plays a key role in</br>early stages of T cell activation. CTLA-4 antagonizes</br>CD28 mediated co-stimulation by binding to CD80</br>(also known as B7.1) and/or CD86 (also known as</br>B7.2).18 Overexpression of CTLA-4, dampens activa-</br>tion of T cells by competing CD28 in binding to CD80</br>and/or CD86.18 The importance of CTLA-4 has been</br>demonstrated by animal studies involving CTLA-4</br>knockout mice. It was noted that CTLA-4 knockout</br>mice developed severe/fatal myocarditis which was</br>likely a result of the lymphocytic inﬁltration of cyto-</br>toxic T-cells.27 L€aubli et al28 were able to demonstrate</br>that lymphocytic inﬁltrates involve the same T-cell</br>lineage which was present</br>in both tumor and</br>myocardium using immunohistochemistry analysis.</br>Endomyocardial biopsy and postmortem analysis</br>conﬁrmed cytotoxic T-cells, macrophages and signs of</br>myocardial ﬁbrosis,</br>suggesting direct myocardial</br>injury.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    8
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br></br>S. Upadhrasta et al. / Chronic Diseases and Translational Medicine 5 (2019) 6e14</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Table 1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
</br>List of ICIs, approval year, mechanism of action and current clinical indications.</br></br>Mechanism of action</br></br>Target</br></br>Indications</br></br>Drug</br></br>Pembrolizumab</br></br>(
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Keytruda
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
)</br></br>Year</br>approved</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2014
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br></br>A mAb that binds to the PD-1</br></br>PD-1</br></br>receptor and blocks its interaction</br>with PD-L1 and PD-L2, releasing</br>PD-1 pathway-mediated inhibition</br>of the immune response leading to</br>T cell proliferation and cytokine</br>production.</br></br>Nivolumab</br>(Opdiv)</br></br>Atezolizumab</br>(Tecentriq)</br></br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Avelumab


    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
(
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Bavencio
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
)</br></br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Durvalumab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
</br>(
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Imﬁnzi
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
)</br></br>Ipilimumab</br>(
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Yervoy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
)</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2014
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br></br>A mAb that binds to the PD-1</br></br>PD-1</br></br>receptor and blocks its interaction</br>with PD-L1 and PD-L2, releasing</br>PD-1 pathway-mediated inhibition</br>of the immune response leading to</br>T cell proliferation and cytokine</br>production.</br></br>A mAb that binds to PD-L1 and</br>blocks its interaction with both</br>PD1 and B7.1 receptors, which</br>suppresses T-cell activity and</br>cytokine production.</br></br>A mAb that binds to PD-L1 and</br>blocks its interaction with both</br>PD1 and B7.1 receptors, which</br>suppresses T-cell activity and</br>cytokine production.</br></br>A mAb that binds to PD-L1 and</br>blocks its interaction with both</br>PD1 and B7.1 receptors, which</br>suppresses T-cell activity and</br>cytokine production.</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2016
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2017
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2017
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br></br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Melanoma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
</br>NSCLC</br>HNSCC</br>cHL</br>PMBCL</br>Urothelial carcinoma</br>Microsatellite instability-high cancer</br>Gastric cancer</br>Cervical cancer</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    HCC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br>
<mark class="entity" style="background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Metastatic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">NORP</span>
</mark>
 melanoma</br>NSCLC</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Advanced RCC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
</br>cHL</br>HNSCC</br>Urothelial carcinoma</br>
<mark class="entity" style="background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Metastatic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">NORP</span>
</mark>
 colorectal cancer</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    HCC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br>Metastatic urothelial carcinoma</br>NSCLC</br></br>PD-L1</br></br>PD-L1</br></br>Metastatic Merkel cell carcinoma</br>Metastatic urothelial carcinoma</br></br>PD-L1</br></br>Metastatic urothelial carcinoma</br>NSCLC</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2011
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
</br></br>A mAb that binds to 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CTLA-4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 and</br></br>CTLA-4</br></br>Metastatic melanoma</br></br>blocks interaction of CTLA-4 with</br>its ligands CD80/CD86. Blockade</br>of 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CTLA-4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 has been shown to</br>augment T-cell activation and</br>proliferation, including the</br>activation and proliferation of</br>tumor inﬁltrating T-effector cells.</br></br>ICIs: immune checkpoint inhibitors; mAb: monoclonal antibody; PD-1: programmed cell death 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
; PD-L1: programmed cell death ligand 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
; PD-L2:</br>programmed cell death ligand 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
; NSCLC: non-small-cell lung cancer; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    HNSCC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
: head and neck squamous cell carcinoma; cHL: classical Hodgkin</br>lymphoma; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    PMBCL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
: primary mediastinal B-cell lymphoma; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    HCC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
: hepatocellular carcinoma; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    RCC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
: renal cell carcinoma; CTLA-4: cytotoxic</br>T lymphocyte associated antigen 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
; CD: cluster of differentiation.</br></br>It can be inferred from these studies that there are</br>at</br>least</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    two
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 mechanisms of developing 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
-related</br>myocarditis. The ﬁrst mechanism is the breakdown of</br>immune tolerance to the heart mediated by CTLA-4</br>and PD-1 pathways as described above.29 The 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    second
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORDINAL</span>
</mark>
</br>mechanism involves expansion of T-cells targeting a</br>common antigen shared by the tumor and the heart.</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Johnson et al30
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 reported 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    two
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 cases of lethal myocarditis</br></br>when combination of ipilimumab and nivolumab was</br>used in treatment of melanoma. They found that se-</br>lective T-cell activation happened in response to a</br>common antigen, as T-cell populations inﬁltrating the</br>myocardium were identical to those present in tumors</br>and skeletal muscle. They also noted that high levels of</br>muscle-speciﬁc antigens such as desmin and troponin</br>were observed in the population group.29,30 Overall,</br></br>S. Upadhrasta et al. / Chronic Diseases and Translational Medicine 5 (2019) 6e14</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    9
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br></br>this leads to the inference that common antigens be-</br>tween tumor and heart exist and ICIs can enhance T-</br>cell</br>lead to lethal</br>myocarditis.29,30</br></br>function and thus</br></br>effector</br></br>the melanoma</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    One
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 of the ﬁrst tumor-associated antigens recog-</br>associated antigen-A</br>nized was</br>(
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    MAGE-A
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
) antigen, and it has been expressed in</br>multiple cancers and associated with poor prognosis.</br>trials</br>Although clinical</br>involving 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    anti-MAGE-A

    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
human leukocyte</br>antigen (HLA)-A0201-restricted</br>T-cell receptor (
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
) showed clinical regression of</br>cancer, their use has been shown to be associated with</br>neurotoxicity and cardiotoxicity.31,32 This was likely</br>related to the homology between targeted antigens and</br>cardiomuscular proteins.32</br></br>Epidemiology</br></br>Clinical presentation</br></br>Cardiac involvement from 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 therapy is variable</br>and potential toxicities include myocardial, pericardial,</br>and conduction system involvement. Prevalence is</br>much higher in patients on combination immuno-</br>therapy. Pericardial disease, Takotsubo cardiomyopa-</br>thy, and conduction abnormalities including complete</br>heart block have also been reported with 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 use,</br>although they occur less frequently as compared to</br>myocarditis (
<mark class="entity" style="background: #f0d0ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Table 2).11,12,33e37

Signs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">WORK_OF_ART</span>
</mark>
 and symptoms vary depending on the type of</br>cardiac toxicity and the degree of involvement. Patient</br>could present with pericardial pain in case of pericar-</br>ditis, shortness of breath in the setting of pulmonary</br>edema from myocarditis or palpitations, pre-syncope</br>and syncope in the setting of arrhythmias.</br></br>Cardiac IRAEs are known to occur less frequently</br>than IRAEs in other organ systems and are known to</br>be clinically challenging to diagnose and treat when</br>they do occur.</br></br>Myocarditis related to 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 use has emerged as an</br>important 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    IRAE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 from a review of recent case reports,</br>clinical trials and safety databases. In 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2016
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Johnson
et al30
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 reported 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    two
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 cases of patients with melanoma in</br>whom fatal myocarditis developed after the ﬁrst dose</br>of</br>ipilimumab and nivolumab. Pharmacovigilance</br>studies show that myocarditis occurred in 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.27%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 of</br>patients treated with combination of ipilimumab and</br>nivolumab. Other studies have looked into the safety</br>databases of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Bristol-Myers-Squibb
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 to identify the</br>occurrence of these events in patients treated with</br>nivolumab, ipilimumab, or both. Among 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    20,594
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 pa-</br>tients treated with ICIs, 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    18
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 drug-related myocarditis</br></br>cases (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.09%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
) were reported. Patients who received</br>combination ICIs had more severe and frequent</br>myocarditis than those who received nivolumab alone</br>(
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.27%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 vs. 0.06%).12,30 Although combination 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br>therapy has shown a signiﬁcant anti-tumor effect in the</br>treatment of multiple cancers, discontinuation has been</br>required in 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    nearly 40%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 of treated patients due to car-</br>diac side effects.38</br></br>Prevalence</br></br>In 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2018
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
, a meta-analysis to evaluate the adverse drug</br>reactions associated with ICIs was published. The</br>analyzed data were from large academic medical cen-</br>ters, the global 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    World Health Organization
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 (WHO)</br>pharmacovigilance program and all published 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 clin-</br>ical trials in cancer patients internationally that used</br>anti-PD-1/PD-L1 and anti-CTLA-4 agents. Out of 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    613
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
-related fatal events reported 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    from 2009
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
 through</br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    January 2018
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
 in WHO pharmacovigilance database</br>(
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Vigilyze
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
), 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    52
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 were cardiac IRAEs, including 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 caused</br>by anti-CTLA-4 antibody, 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    27
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 caused by anti-PD-1/PD-</br>L1 antibody, and 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    22
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 caused by the combination of anti-</br>CTLA-4 antibody and anti-PD-1/PD-L1 antibody.</br>Myocarditis had the highest fatality rate at 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    52
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    39.7%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
) of</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    131
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 reported cases. Retrospective review of 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    3545
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 pa-</br>tients treated with ICIs at 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    7
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 academic centers revealed a</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.6%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 fatality rate; cardiac and neurologic events were</br>especially prominent (43%).39</br></br>In 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Table 3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
, we present a brief analysis of adverse</br>drug reactions (ADRs) for the 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    six
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 commonly used ICIs,</br>contained within 
<mark class="entity" style="background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    VigiBase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PRODUCT</span>
</mark>
, the 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    WHO
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 global database</br>for ADRs. A total of 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    106,025
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 ADRs were reported,</br>2215 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2.09%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
) were cardiac. Among the cardiac ADRs,</br>myocarditis accounted for 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    14.1%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    312
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 cases), followed</br>by pericardial disease including pericarditis, pericar-</br>dial effusions and cardiac tamponade cases which</br>accounted for 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    13.6%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    302
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 cases). These were followed</br>by conduction abnormalities (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    152
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 cases, 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    6.86%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
) and</br>stress cardiomyopathy (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    16
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 cases, 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.72%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
). From this</br>brief analysis,</br>it appears myocarditis is the most</br>common type of cardiac toxicity with immune check-</br>point</br>inhibitors. Combination ICIs and associated</br>ADRs were not part of our analysis; however, studies</br>by 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Salem
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
 et al40 have veriﬁed the increased incidence</br>of cardiac IRAEs with combination therapy. Further</br>details on the proportions of cardiac ADRs for each</br>speciﬁc immunotherapy agent are listed in 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Table 3

    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
(data obtained from VigiAccess).41</br></br>A similar study published in 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2018
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
 by 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Salem
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
 et al40</br>evaluated the IRAEs associated with ICIs through</br>analysis of 
<mark class="entity" style="background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    VigiBase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PRODUCT</span>
</mark>
. The association between ICIs and</br></br>10</br></br>S. Upadhrasta et al. / Chronic Diseases and Translational Medicine 5 (2019) 6e14</br></br>Table 2</br>Summary of approach and treatment strategies for 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 induced cardiotoxicities.12</br></br>Cardiac</br>toxicity</br></br>Clinical presentation</br></br>Mechanism of cardiotoxic</br>effects</br></br>
<mark class="entity" style="background: #ffeb80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Myocarditis

Presentation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">EVENT</span>
</mark>
 can be challenging.</br></br>Not fully understood. Post-</br></br>Can present with 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    HF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
,</br>pulmonary edema, cardiogenic</br>shock, multiorgan failure,</br>ventricular arrhythmias.</br></br>mortem analysis has shown</br>inﬂammatory cell inﬁltrate,</br>increase in extracellular</br>space volume, and loss of</br>cardiomyocytes. Studies</br>have conﬁrmed the</br>presence of both CD4-</br>positive and 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CD8-positive

    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
T cells.</br></br>Clinical approach</br></br>Clinical management</br></br>Depends on the</br>presentation</br>(asymptomatic to</br>fulminant myocarditis).</br>Diagnostic tests</br>include 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    EKG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
,</br>biomarkers, cardiac</br>imaging (ECHO or</br>cardiac MRI). If still</br>uncertain,</br>endomyocardial biopsy</br>can be preformed.</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1st
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
: Stop 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 depending on the</br></br>severity of toxicity.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2nd
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
: IV methylprednisolone</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    500e1000 mg
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">QUANTITY</span>
</mark>
 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    daily
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
 until</br>clinically stable, followed by</br>oral prednisone 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 mg/kg daily,</br>and wean as tolerated. For</br>non-steroid responders,</br>consider mycophenolate</br>mofetil or inﬂiximab, anti-</br>thymocyte globulin or</br>intravenous immunoglobulin.</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    3rd
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORDINAL</span>
</mark>
: Use of conventional cardiac</br></br>treatments per standard ACC</br>guidelines.</br></br>Pericardial</br>disease</br></br>Can occur in isolation with</br>typical pericardial pain or</br>alongside with myocardial</br>involvement with</br>perimyocarditis, and can be</br>complicated by pericardial</br>effusion and tamponade.</br></br>Not fully understood.</br></br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Diagnostic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 tests include</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1st
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
: Stop 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 therapy, and</br></br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    EKG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, cardiac</br>biomarkers and cardiac</br>imaging.</br></br>consider re-challenging with</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 therapy only if clinically</br>stable and when clinical</br>pericarditis is excluded.</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2nd
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORDINAL</span>
</mark>
: Consider intravenous</br></br>methylprednisolone 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    500e1000
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br>mg 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    daily
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
 until clinically stable,</br>followed by oral prednisone</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 mg/kg once daily, and</br>wean as tolerated.</br></br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Arrhythmias


    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
Can present in wide ranges, from</br></br>Underlying myocarditis with</br></br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Diagnostic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 test: 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    EKG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1st
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
: Stop 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 therapy, and</br></br>complete atrioventricular</br>block (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    third
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORDINAL</span>
</mark>
 degree heart</br>block) to atrial and ventricular</br>tachyarrhythmias.</br></br>inﬂammation being the</br>substrate for triggered</br>arrhythmias, inﬂammation</br>of the 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    His-Purkinje
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 system</br>being the trigger for re-</br>entry arrhythmias,</br>increased systemic</br>inﬂammation leading to</br>arrhythmias without</br>myocarditis.</br></br>consider re-challenging with</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 therapy only if clinically</br>stable and after myocarditis is</br>excluded. Immune suppression</br>is not applicable in the absence</br>of myocarditis.</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2nd
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
: Management of arrhythmias</br></br>per 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ACC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 guidelines.</br></br>ICIs: immune checkpoint inhibitors; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    HF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
: heart failure; CD: cluster of differentiation; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    EKG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
: electrocardiogram; ECHO: echocardiogram; MRI:</br>magnetic resonance imaging; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    IV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
: intravenous; ACC: 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    American College of Cardiology
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
.</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Table 3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
</br>Incidence of ADRs as reported within 
<mark class="entity" style="background: #ff8197; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    the VigiAccess/VigiBase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">LAW</span>
</mark>
 from 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    the World Health Organization
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 global database for ADRs.</br></br>Drug</br></br>Total ADRs, n</br></br>Cardiac ADRs, n (%)</br></br>Proportion of cardiac ADRs</br></br>Pembrolizumab</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Nivolumab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Atezolizumab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Avelumab

    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>

<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Durvalumab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Ipilimumab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    25,028
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    49,506
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    3627
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    505
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1329
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    26,030
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br></br>Total</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    106,025
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br></br>ADR: adverse drug reactions.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    497
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1.99
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1103
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2.23
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    94
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2.59
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    16
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    3.17
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    34
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2.56
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    471
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1.81
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2215
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2.09
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br></br>Myocarditis,</br>n (%)</br></br>Pericardial</br>disease, n (%)</br></br>Conduction</br>abnormalities, n (%)</br></br>Stress cardiomyopathy,</br>n (%)</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    80
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    16.10
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    148
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    13.40
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    10
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    10.60
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    25.00
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    11.80
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    69
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    14.60
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    80
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    16.10
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    155
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    14.10
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    16
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    17.00
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    12.50
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    7
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    11.80
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    42
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    8.92
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    34
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    6.84
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    71
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    6.44
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    6
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    6.38
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    12.50
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>0 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.00
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    39
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    8.28
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    5
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1.00
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    6
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.54
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1.06
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.00
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.00
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.85
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    312
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    14.10
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    302
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    13.60
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    152
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    6.86
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    16
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.72
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
)</br></br>S. Upadhrasta et al. / 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Chronic
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 Diseases and Translational Medicine 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    5
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (2019) 6e14</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    11
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br></br>cardiovascular IRAEs has been studied using odds</br>ratios and information component (
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    IC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
; an indicator</br>value for disproportionate 
<mark class="entity" style="background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Bayesian
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">NORP</span>
</mark>
 reporting that</br>compares observed and expected values to ﬁnd drug-</br>adverse effect combinations that have been reported</br>more often than one would expect. A value of &gt;0 for</br>the lower end of the IC 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    95%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 credibility interval</br>[
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    IC025
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
] is deemed signiﬁcant). Drug-related adverse</br>events were most described with myocarditis (report-</br>ing odds ratio, 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    11.21
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 [
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    95%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 CI: 9.36e13.43]; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    IC025
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
,</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    3.20
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
), pericardial disease (reporting odds ratio, 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    3.80
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br>[
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    95%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 CI: 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    3.08e4.62
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
]; 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    IC025
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1.63
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
), and vasculitis</br>ratio, 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1.56
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 [
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    95%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 CI:1.25e1.94];</br>(reporting odds</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    IC025
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 0.03).42</br></br>Risk factors</br></br>It is still uncertain which, if any, pre-exiting risk</br>factors might affect the incidence of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 mediated</br>cardiotoxicity. In a case-series by 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Mahmood
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 et al,43</br>myocarditis appeared to be more common in in-</br>dividuals with pre-existing cardiovascular risk factors;</br>however, 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    70%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 of the patients who developed myocar-</br>ditis had a normal left ventricular ejection fraction</br>before initiating therapy.</br>It was also noted that</br>myocarditis presented early, most commonly 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    30 days
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
</br>after</br>initiating ICIs and 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    81%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 presented within 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    3
months
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
. In contrast, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Moslehi et al44
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 recently reported</br>on the absence of concomitant cardiovascular or anti-</br>diabetic drugs in 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    75%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 of all cases of myocarditis and</br>suggested that pre-existing cardiac disorders or car-</br>diovascular risk factors would not predispose patients</br>to develop 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
-associated myocarditis.</br></br>Nonetheless, there is enough concerning data, so</br>developing a surveillance protocol for the early phases</br>and post initiation of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 therapy is imperative. Un-</br>fortunately, as described above a normal pre-treatment</br>echocardiogram does not reliably predict who will</br>develop myocarditis. Follow-up of patients with repeat</br>echocardiogram (ECHO), cardiac biomarkers and/or</br>cardiac MRI in the initial and later phases of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br>therapy would be beneﬁcial in the evaluation of late</br>onset cardiotoxicity.</br></br>Patients with autoimmunity can develop subclinical or</br>subacute myocarditis. It has been noted that patients with</br>autoimmune disorders are usually excluded from clinical</br>trials with 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 therapy. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Approximately 14%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 of patients</br>with lung cancer have a concurrent diagnosis of autoim-</br>mune disease.45 Menzies et al46 and 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Johnson et al47

    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
demonstrated that 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    20%e30%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 of patients with pre-</br>existing autoimmune diseases experienced an autoim-</br>mune ﬂare after being treated with anti-PD-1 antibodies</br></br>or anti-CTLA-4 antibodies. However,</br>the authors</br>concluded that 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 therapy was feasible for patients with</br>certain types of pre-existing autoimmune conditions.</br></br>Interestingly, researchers observed that although</br>men are more likely to derive beneﬁt from cancer</br>immunotherapy than women,</br>they are also more</br>affected by IRAEs than women.40,42,48 Conversely,</br>autoimmune diseases affect women more than men and</br>the prevalence of cardiovascular disease or risk factors</br>is higher in men than women, especially in the pre-</br>menopausal age group. Further studies should ensure</br>inclusion of women for a clear assessment of sex</br>dysmorphism in 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
-related 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    IRAEs.42

Diagnosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 and management</br></br>Diagnosis</br></br>(i.e.</br></br>Cardiotoxicity associated with 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 use is known for</br>its wide range of clinical presentations depending upon</br>local vs.</br>the extent of cardiac involvement</br>diffuse). This makes it unfavorable for early diagnosis;</br>however, with increasing awareness of cardiotoxicity</br>as an important 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    IRAE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, certain general characteristics</br>of their presentations can be used as clinical markers of</br>disease onset. For example, myocarditis associated</br>with 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 use has almost always presented with an</br>elevation in cardiac biomarkers such as troponin and</br>creatinine kinase 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    MB
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 (
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
-MB).33,49 The degree of</br>troponin elevation could also correlate with major</br>adverse cardiac events (
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    MACE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
) outcomes as shown in</br>a prospective observational study by 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Mahmood
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 et al.43</br>There was a 
<mark class="entity" style="background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    4-fold
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PRODUCT</span>
</mark>
 increased risk of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    MACE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 with</br>troponin T of 1.5 ng/ml (hazard ratio: 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    4.0
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
; 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    95%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
</br>conﬁdence interval: 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1.5
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 to 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    10.9
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
; P ¼ 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.003
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
). Addi-</br>tionally, patients who experienced 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    MACE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 myocarditis</br>were found to have a higher admission, peak and</br>discharge troponin T value. The diagnostic accuracy</br>for troponin T and 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    MACE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 was highest for discharge/</br>ﬁnal troponin T (area under the curve [AUC]: 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.81
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
;</br>P ¼ 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.004
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
) and fair for admission and peak troponin T</br>(AUC: 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.76
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
, P ¼ 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.010
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
; and 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    AUC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
: 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.76
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
, P ¼ 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    0.010
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
,</br>respectively).</br></br>Electrocardiogram (
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    EKG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
) and echocardiogram are</br>readily available diagnostic tools for diagnosis of</br>myocarditis. Nonspeciﬁc T-wave changes are the most</br>common 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    EKG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 abnormalities seen in myocarditis;</br>however, new onset conduction blocks</br>including</br>complete heart blocks, arrhythmias, ST elevations</br>mimicking</br>infarction</br>(
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    STEMI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
) and new onset Q waves may also be seen.50</br>The sensitivity of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    EKG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 in myocarditis is 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    only 47%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
;</br></br>ST elevation myocardial</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    12
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br></br>S. Upadhrasta et al. / Chronic Diseases and Translational Medicine 5 (2019) 6e14</br></br>however, it is important to note that data pertaining</br>to myocarditis related 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    EKG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 changes in the setting of</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 therapy are limited.51 In a recent retrospective</br>study, new 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    EKG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 changes and systolic dysfunction</br>were observed in 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    up to 40% and 79%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 respectively,</br>of all patients diagnosed with 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
-associated car-</br>diotoxicity.33,52 Evidence supports the use of longi-</br>tudinal global strain measured by echocardiogram</br>to detect cardiotoxicity in patients undergoing</br>chemotherapy.53,54</br></br>The role of cardiac MRI in the diagnosis of cardiac</br>toxicity is debatable. While some studies have not</br>found cardiac MRI to be particularly useful in the</br>diagnosis of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
-mediated cardiotoxicity,</br>they still</br>continue to recommend its use to differentiate 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI-

    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
related myocarditis from other etiologies of cardiac</br>dysfunction.34 However, it is important to note that</br>recent studies by 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Ganatra
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 et al55 showed that cardiac</br>MRI is highly sensitive and speciﬁc and can be used as</br>a primary modality for diagnosis of suspected 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br>associated myocarditis. Both 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    T1/T2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 weighted images</br>and gadolinium based images compare similarly in the</br>diagnosis of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 mediated cardiotoxicity.55,56</br></br>Histological analysis of endomyocardial biopsy in</br>patients with 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
-related myocarditis found lympho-</br>cytic inﬁltrates within the myocardium, cardiac sinus,</br>and the atrioventricular nodes explaining the com-</br>plete heart block demonstrated in these patients.</br>þ</br>Increased expression of CD8</br>macrophages were</br>suggesting</br>direct myocardial injury by hyperactivated cytotoxic</br>T cells as a possible mechanism of myocardial</br>injury.33 It is important to note that endomyocardial</br>biopsy, although has diagnostic value, has very</br>limited clinical value due to the invasiveness of the</br>procedure.</br></br>T cells and CD68</br></br>observed</br></br>also</br></br>þ</br></br>Management</br></br>Glucocorticoid therapy has been shown to improve</br>left ventricular function measured as ejection fraction</br>by 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    50%
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERCENT</span>
</mark>
 in the setting of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 mediated cardiotoxicity.33</br>There are various proposed treatment regimens ranging</br>from 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    30
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 mg of oral prednisone 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    daily
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
 for isolated</br>pericardial disease to 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1000
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 mg of intravenous methyl-</br>prednisolone daily for</br>fulminant myocardial dis-</br>ease.33,57 Alternatively, oral prednisone at an initial</br>dose of 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1e2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 mg/kg daily followed by a slow taper has</br>been shown to be of beneﬁt in patients without fulmi-</br>nant myocarditis.33,58 Other immunosuppressive regi-</br>mens that can be used in steroid non-responders</br>include plasmapheresis, intravenous immunoglobulins,</br></br>globulin</br></br>tacrolimus</br></br>(ATG), mycophenolate</br>anti-thymocyte</br>and inﬂiximab.37,49,58,59 Data</br>mofetil,</br>supporting the use of</br>these therapies are lacking</br>which largely limits their use in the treatment of car-</br>diac toxicities.</br></br>It is of paramount importance to develop guidelines</br>for early diagnosis and management of cardiotoxicity</br>associated with ICIs. Currently, there are no deﬁnite</br>treatment guidelines for these potentially fatal side</br>effects although high dose steroids remain the corner-</br>stone of therapy, as with IRAEs of any other organ</br>system. Algorithms for diagnosing and managing</br>IRAEs including 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
-related myocarditis have been</br>proposed.30,55</br></br>Cardio-immuno-oncology: the future prospective</br></br>Time has come for cardiologists, oncologists and</br>immunologists to work in close collaboration to di-</br>agnose and manage cardiotoxicity associated with 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br>use, in a timely manner. The use of ICIs in the treatment</br>of different cancers is predicted to increase in the near</br>future and it is safe to assume so will cardiotoxicity. It is</br>imperative to spread awareness about the manifestations</br>of cardiotoxicity amongst clinicians. Close follow-up of</br>patients on 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 with serial cardiac biomarkers, EKGs</br>and cardiac echocardiograms should be incorporated</br>into guideline management recommendations for pa-</br>tients</br>to</br>acknowledge that the lack of prospective and cohort</br>studies is a limitation as currently most of the data are</br>observed from case reports and case series. Continued</br>research in understanding the pathophysiology of ICI-</br>related cardiotoxicity has the potential to help develop</br>new therapeutic modalities. Future studies are needed to</br>assess the long-term cardiotoxicity of ICIs. Together, we</br>can make a difference!</br></br>receiving 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ICI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br></br>important</br></br>therapy.</br></br>is</br></br>It</br></br>Conﬂicts of interest</br></br>None declared.</br></br>References</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Varricchi G
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Galdiero MR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Tocchetti CG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. Cardiac toxicity of</br>immune checkpoint inhibitors: cardio-oncology meets immu-</br>nology. Circulation. 2017;136:1989e1992.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Mahoney KM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Freeman GJ
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    McDermott DF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. The next immune-</br>checkpoint inhibitors: 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    PD-1/PD-L1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 blockade in melanoma. Clin</br>Ther. 2015;37:764e782.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Allison JP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Hurwitz AA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Leach DR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
. Manipulation of cos-</br>timulatory signals to enhance antitumor T-cell responses. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Curr

    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>

<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Opin Immunol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 1995;7:682e686.</br></br>S. Upadhrasta et al. / Chronic Diseases and Translational Medicine 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    5
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (2019) 6e14</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    13
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. Eigentler 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    TK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Hassel JC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Berking C
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, et al. Diagnosis, monitoring</br>and management of immune-related adverse drug reactions of</br>anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7e18.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    5
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Hurst JH
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
. Cancer immunotherapy innovator 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    James Allison
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 re-</br>ceives the 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2015
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lasker~
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>

<mark class="entity" style="background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    DeBakey
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PRODUCT</span>
</mark>
 clinical medical research</br>award. J Clin Invest. 2015;125:3732e3736.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    6
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Herbst RS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Soria JC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Kowanetz M
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, et al. Predictive correlates of</br>response to the anti-PD-L1 antibody MPDL3280A in cancer</br>patients. Nature. 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2014;515:563e567
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    7
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Fehrenbacher L
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Spira A, Ballinger M
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, et al. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Atezolizumab
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
</br>versus docetaxel for patients with previously treated non-</br>small-cell</br>(POPLAR): a multicentre, open-</br>Lancet.</br>label,</br>2016;387:1837e1846.</br></br>lung cancer</br></br>randomised</br></br>controlled</br></br>phase</br></br>trial.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    8
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Nayak L
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Iwamoto FM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    LaCasce A
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, et al. PD-1 blockade with</br>nivolumab in relapsed/refractory primary central nervous system</br>and testicular lymphoma. Blood. 2017;129:3071e3073.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    9
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Varricchi G
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Marone G
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, Mercurio V, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Galdiero MR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Bonaduce D,
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
</br>inhibitors and cardiac</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Curr Med
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br>Chem.</br></br>Immune checkpoint</br>issue.</br></br>emerging</br></br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Tocchetti CG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
.</br>toxicity:</br>an</br>2018;25:1327e1339.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    10
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Maawy AA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Ito F. Future
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 of immune checkpoint inhibitors. In:</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Ito F
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, Ernstoff M, eds. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Immune Checkpoint Inhibitors in Cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
.</br>
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    St. Louis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
, MO: 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Elsevier, Inc
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
; 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2019:227e243
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    11
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Della Vittoria Scarpati G
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Fusciello
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 C, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Perri F
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, et al. Ipilimumab</br>in the treatment of metastatic melanoma: management of</br>adverse events. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Onco Targets Ther
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2014;7:203e209
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    12
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lyon AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Yousaf N
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Battisti NML
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Moslehi J
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Larkin J. Immune
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br>checkpoint inhibitors and cardiovascular toxicity. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lancet Oncol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
.</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2018;19:e447ee458
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    13
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Costa R
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Carneiro BA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Agulnik M
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, et al. Toxicity proﬁle of</br>approved anti-PD-1 monoclonal antibodies in solid tumors: a</br>systematic review and meta-analysis of randomized clinical tri-</br>als. Oncotarget. 2017;8:8910e8920.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    14
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. Heinzerling L, Ott PA, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Hodi FS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, et al. Cardiotoxicity associated</br>with 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CTLA4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 and PD1 blocking immunotherapy. J Immunother</br>Cancer. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2016;4:50
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    15
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Tocchetti CG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Galdiero MR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Varricchi G. Cardiac
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 toxicity in</br>patients treated with immune checkpoint inhibitors: it is now</br>J Am Coll Cardiol.</br>time</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2018;71:1765e1767
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>cardio-immuno-oncology.</br></br>for</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    16
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. Brahmer 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    JR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lacchetti C
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Thompson JA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. Management of</br>immune-related adverse events in patients treated with immune</br>checkpoint</br>inhibitor therapy: 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    American Society of Clinical
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br>Oncology clinical practice guideline summary. J Oncol Pract.</br>2018;14:247e249.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    17
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Haanen JBAG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Carbonnel F
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Robert C
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, et al. Management of</br>toxicities</br>from immunotherapy: 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ESMO Clinical Practice
Guidelines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 for diagnosis, treatment and follow-up. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Ann Oncol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
.</br>2018;29(suppl 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    4):iv264eiv266
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    18
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Walker LS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, Sansom DM. The emerging role of 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CTLA4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 as a cell-</br>extrinsic regulator of T cell responses. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Nat Rev Immunol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
.</br>2011;11:852e863.</br></br>alloimmune</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    19
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Yang J
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Riella LV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Chock S
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, et al. The novel costimulatory</br>in</br>Immunol.</br></br>programmed death ligand 1/B7.1 pathway is functional</br>inhibiting</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2011;187:1113e1119
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    20
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Grabie N
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Gotsman I
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    DaCosta R
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, et al. Endothelial programmed</br>death-1 ligand 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 (PD-L1) regulates CD8þ T-cellemediated</br>injury in the heart. Circulation. 2007;116:2062e2071.</br></br>responses</br></br>vivo.</br></br>in</br></br>J</br></br>checkpoint for autoimmune myocarditis and pneumonitis in</br>MRL mice. J Immunol. 2008;181:2513e2521.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    22
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Wang J
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Okazaki IM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Yoshida T
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, et al. PD-1 deﬁciency results in</br>the development of fatal myocarditis in MRL mice. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Int Immunol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
.</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2010;22:443e452
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    23
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. Waterhouse P, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Penninger JM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Timms E
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, et al. Lymphoprolifer-</br>ative disorders with early lethality in mice deﬁcient in 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CTLA-4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
.</br>Science. 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1995;270:985e988
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    24
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. Tarrio ML, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Grabie N
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Bu D
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, Sharpe AH, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lichtman AH
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
. PD-1</br>protects against inﬂammation and myocyte damage in T cell-</br>mediated myocarditis. J Immunol. 2012;188:4876e4884.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    25
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Nishimura H
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Okazaki T
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Tanaka Y
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, et al. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Autoimmune
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 dilated</br>cardiomyopathy in PD-1 receptor-deﬁcient mice. Science.</br>2001;291:319e322.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    26
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Nishimura H
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Nose M
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Hiai H
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Minato N
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Honjo T. Development
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br>of lupus-like autoimmune diseases by disruption of the PD-1</br>gene encoding an 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    ITIM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 motif-carrying immunoreceptor. Immu-</br>nity. 1999;11:141e151.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    27
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. Tivol EA, Borriello F, Schweitzer AN, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lynch WP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
,</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Bluestone JA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Sharpe
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 AH. Loss of 
<mark class="entity" style="background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CTLA-4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PRODUCT</span>
</mark>
 leads to massive</br>lymphoproliferation and fatal multiorgan tissue destruction,</br>revealing a critical negative regulatory role of 
<mark class="entity" style="background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    CTLA-4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PRODUCT</span>
</mark>
. Im-</br>munity. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1995;3:541e547
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    28
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. L€aubli H, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Balmelli C
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Bossard M
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Pﬁster O
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Glatz K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
,</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Zippelius A. Acute
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 heart failure due to autoimmune myocarditis</br>under pembrolizumab treatment for metastatic melanoma. J</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Immunother Cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
. 2015;3:11.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    29
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Tajiri K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Aonuma K
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Sekine I. Immune
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 checkpoint inhibitor-</br></br>related myocarditis. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Jpn J Clin Oncol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
. 2018;48:7e12.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    30
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Johnson
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 DB, Balko JM, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Compton ML
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, et al. Fulminant</br>myocarditis with combination immune checkpoint blockade. N</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Engl J Med
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
. 2016;375:1749e1755.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    31
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Brichard VG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, Louahed J, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Clay TM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. Cancer regression and</br>toxicity cases after anti-MAGE-A3 TCR gene</br></br>neurological</br>therapy. J Immunother. 2013;36:79e81.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    32
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. Schooten E, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Di Maggio
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 A, van 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Bergen
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 En Henegouwen PMP,</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Kijanka MM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
. MAGE-A antigens as targets for cancer immu-</br>notherapy. Cancer Treat Rev. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2018;67:54e62
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    33
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Yang S
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Asnani A. Cardiotoxicities
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 associated with immune</br></br>checkpoint inhibitors. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Curr Probl Cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 2018;42:422e432.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    34
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. Semper H, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Muehlberg F
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, Schulz-Menger J, Allewelt M, Grohe 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    C.
Drug
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
-induced myocarditis after nivolumab treatment in a patient</br>with 
<mark class="entity" style="background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    PDL1-
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">NORP</span>
</mark>
 negative squamous cell carcinoma of the lung. Lung</br>Cancer. 2016;99:117e119.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    35
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Geisler BP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Raad RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, Esaian D, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Sharon E
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, Schwartz DR. Apical</br>ballooning and cardiomyopathy in a melanoma patient treated</br>with ipilimumab: a case of takotsubo-like syndrome. J Immun-</br>other 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2015;3:4
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    36
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. de Almeida DVP, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Gomes JR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Haddad FJ
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Buzaid AC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. Immune-</br>mediated pericarditis with pericardial tamponade during nivo-</br>lumab therapy. J Immunother. 2018;41:329e331.</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    37
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Norwood TG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Westbrook BC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Johnson DB
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, et al. Smoldering</br>myocarditis following immune checkpoint blockade. J Immun-</br>other 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2017;5:91
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    38
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Larkin J
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Hodi FS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Wolchok JD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. Combined nivolumab and ipi-</br>limumab or monotherapy in untreated melanoma. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    N Engl J Med
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
.</br>2015;373:1270e1271.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    39
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Wang DY
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Salem JE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
, 
<mark class="entity" style="background: #feca74; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Cohen JV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">GPE</span>
</mark>
, et al. Fatal toxic effects asso-</br>ciated with immune checkpoint inhibitors: a systematic review</br>and meta-analysis. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    JAMA Oncol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
. 2018;4:1721e1728.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    21
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lucas
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">NORP</span>
</mark>
 JA, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Menke J, Rabacal WA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Schoen FJ
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Sharpe
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 AH,</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Kelley
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 VR. Programmed death ligand 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
 regulates a critical</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    40
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Salem JE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Manouchehri
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 A, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Moey M
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, et al. Cardiovascular tox-</br>inhibitors: an</br></br>icities associated with immune checkpoint</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    14
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
</br></br>S. Upadhrasta et al. / Chronic Diseases and Translational Medicine 5 (2019) 6e14</br></br>observational, retrospective, pharmacovigilance study. Lancet</br>Oncol. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2018;19:1579e1589
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    41
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    VigiAccess
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
</br></br>(n.d.).</br></br>http://www.vigiaccess.org/.</br></br>Accessed</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    December 3, 2018
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    42
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Varricchi G
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Galdiero MR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Mercurio V
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Bonaduce D,
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Marone G
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Tocchetti CG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. Pharmacovigilating cardiotoxicity of</br>inhibitors. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lancet Oncol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 2018;19:</br>immune</br>1545e1546.</br></br>checkpoint</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    43
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Mahmood SS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Fradley MG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Cohen JV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, et al. Myocarditis in</br>patients treated with immune checkpoint inhibitors. J Am Coll</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Cardiol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2018;71:1755e1764
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    44
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Moslehi

JJ
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Salem JE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Sosman JA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lebrun-Vignes B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
,</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Johnson
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 DB. Increased reporting of fatal immune checkpoint</br>inhibitor-associated myocarditis. Lancet. 2018;391:933.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    45
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Khan SA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Pruitt SL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Xuan L
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, Gerber DE. Prevalence of auto-</br>immune disease among patients with lung cancer: implications</br>for immunotherapy treatment options. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    JAMA Oncol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 2016;2:</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1507e1508
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    46
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. Menzies AM, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Johnson
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 DB, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Ramanujam S
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, et al. Anti-PD-1</br>therapy in patients with advanced melanoma and preexisting</br>autoimmune disorders or major toxicity with ipilimumab. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Ann
Oncol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
. 2017;28:368e376.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    47
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Johnson
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 DB, Sullivan RJ, 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Menzies AM
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Immune
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 checkpoint</br>inhibitors in challenging populations. Cancer. 2017;123:</br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    1904e1911
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    48
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Abdel-Rahman O.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 Does a patient's sex predict the efﬁcacy of</br></br>cancer immunotherapy? 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lancet Oncol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
. 2018;19:716e717.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    49
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Reddy N
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Moudgil R
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lopez-Mattei
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 JC, et al. Progressive and</br>reversible conduction disease with checkpoint inhibitors. Can J</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Cardiol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2017;33:1335.e13e1335.e15
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    50
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. Gianni M, Dentali F, Grandi AM, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Sumner G
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Hiralal R
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lonn R.
Apical
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 ballooning syndrome or takotsubo cardiomyopathy: a</br>systematic review. Eur 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Heart J. 2006;27:1523e1529
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    51
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Blauwet LA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Cooper LT
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Myocarditis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Prog Cardiovasc
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 Dis.</br></br>2010;52:274e288.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    52
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. Escudier M, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Cautela J
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Malissen N
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, et al. Clinical features,</br>management, and outcomes of immune checkpoint inhibitore</br>related cardiotoxicity. Circulation. 2017;136:2085e2087.</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    53
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Thavendiranathan P
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Poulin F
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Lim KD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Plana JC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Woo A
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
,</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Marwick TH
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. Use of myocardial strain imaging by echocardi-</br>ography for the early detection of cardiotoxicity in patients</br>during and after cancer chemotherapy: a systematic review. J Am</br>
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Coll Cardiol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
. 
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2014;63:2751e2768
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
.</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    54
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Mornos
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
‚ C, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Petrescu L. Early
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 detection of anthracycline-mediated</br>cardiotoxicity: the value of considering both global longitudinal</br>left ventricular strain and twist. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Can J Physiol Pharmacol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
.</br>2013;91:601e607.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    55
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Ganatra S
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Neilan TG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. Immune checkpoint inhibitor-associated</br></br>myocarditis. Oncologist. 2018;23:879e886.</br></br>
<mark class="entity" style="background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    56
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">DATE</span>
</mark>
. Aquaro 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    GD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Perfetti M
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Camastra G
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, et al. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Cardiac MR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 with late</br>gadolinium enhancement in acute myocarditis with preserved systolic</br>function: ITAMY study. J 
<mark class="entity" style="background: #bfeeb7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Am Coll Cardiol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PRODUCT</span>
</mark>
. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2017;70:1977e1987
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    57
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Kushnir
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 I, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Wolf I.
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
 Nivolumab-induced pericardial tamponade: a</br></br>case report and discussion. Cardiology. 2017;136:49e51.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    58
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. Jain V, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Bahia J
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Mohebtash M
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Barac A. Cardiovascular
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
 com-</br>plications associated with novel cancer immunotherapies. 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Curr
Treat Options Cardiovasc Med
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2017;19:36
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    59
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
. 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Frigeri M
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Meyer P
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, 
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Banﬁ C
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
, et al. Immune checkpoint inhibitor-</br>associated myocarditis: a new challenge for cardiologists. Can J</br>
<mark class="entity" style="background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Cardiol
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">ORG</span>
</mark>
. 
<mark class="entity" style="background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    2018;34:92.e1e92.e3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">CARDINAL</span>
</mark>
.</br></br>Edited by 
<mark class="entity" style="background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone">
    Pei-Fang Wei


    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">PERSON</span>
</mark>
</div>
</figure>
</body>
</html>